Literature DB >> 20803741

Meta-analysis for the effect of medical therapy vs. placebo on recovery of idiopathic sudden hearing loss.

Jakob Labus1, Judith Breil, Hartmut Stützer, Olaf Michel.   

Abstract

OBJECTIVES: To estimate the effect of recovery of idiopathic sudden hearing loss under placebo (first aim) and under medical therapy (second aim). STUDY
DESIGN: Systematic review and meta-analysis.
METHODS: A total of 1,674 studies published between January 1974 and April 2009 were found following suggestions in the Cochrane Handbook for Systematic Reviews. After filtering by criteria of Cochrane Collaboration, four trials remained for continuous and two for dichotomous data.
RESULTS: Using Review Manager, weighted mean difference as well as standardized mean effect of hearing recovery were calculated and pooled. The values for weighted mean difference of hearing gain in dB were 0.79, 95% confidence interval (CI) (-2.04-3.61) and for standardized mean effect 0.06, 95% CI (-0.13-0.24), respectively, which computationally favors active treatment, but statistically is not significantly different from no effect (0 dB). This was in accordance to the comparison of descriptive means between recovery under placebo with 14.3 dB and active treatment with 15.8 dB hearing gain. Treatment effect of dichotomous data (hearing gain vs. no hearing gain) suggested a statistically significant better outcome for active treatment; the odds ratio (OR) [fixed] is 2.18 (1.06-4.46).
CONCLUSIONS: In five different statistical analysis methods used, treatment effect of medical therapy was slightly better than recovery under placebo in which spontaneous recovery could be assumed, but no significant effect was detected. Against the background of recovery under placebo of 14.3 dB vs. 15.8 dB hearing gain of active treatment as averages of all measured frequencies, recovery under placebo seems not to have worse outcome than recovery under medical therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20803741     DOI: 10.1002/lary.21011

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  21 in total

1.  Therapeutic effect on idiopathic sudden sensorineural hearing loss with duration of onset more than 3 months.

Authors:  Mingming Wang; Yuechen Han; Zhaomin Fan; Daogong Zhang; Haibo Wang
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2013-01

2.  Hyperbaric oxygen therapy as salvage treatment for sudden sensorineural hearing loss: a prospective controlled study.

Authors:  M Pezzoli; M Magnano; L Maffi; L Pezzoli; P Marcato; M Orione; D Cupi; G Bongioannini
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-16       Impact factor: 2.503

3.  Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments.

Authors:  Gülce Ermutlu; Nilda Süslü; Taner Yılmaz; Sarp Saraç
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-07-29       Impact factor: 2.503

4.  Multivariate analysis of prognostic factors for idiopathic sudden sensorineural hearing loss treated with adjuvant hyperbaric oxygen therapy.

Authors:  Shaobing Xie; Qingfen Qiang; Lingyun Mei; Chufeng He; Yong Feng; Hong Sun; Xuewen Wu
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-10-25       Impact factor: 2.503

Review 5.  Intratympanic corticosteroids for sudden sensorineural hearing loss.

Authors:  Stefan K Plontke; Christoph Meisner; Sumit Agrawal; Per Cayé-Thomasen; Kevin Galbraith; Anthony A Mikulec; Lorne Parnes; Yaamini Premakumar; Julia Reiber; Anne Gm Schilder; Arne Liebau
Journal:  Cochrane Database Syst Rev       Date:  2022-07-22

6.  Efficacy and safety of systemic, high-dose glucocorticoid therapy for idiopathic sudden sensorineural hearing loss : Study protocol for a three-armed, randomized, triple-blind, multicenter trial (HODOKORT).

Authors:  Stefan K Plontke; Matthias Girndt; Christoph Meisner; Iris Böselt; Beatrice Ludwig-Kraus; Michael Richter; Torsten Rahne
Journal:  HNO       Date:  2022-06-20       Impact factor: 1.330

Review 7.  Intratympanic steroids as primary initial treatment of idiopathic sudden sensorineural hearing loss. The Hospital Universitario Ramón y Cajal experience and review of the literature.

Authors:  Tomás Labatut; María José Daza; Antonio Alonso
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-12-20       Impact factor: 2.503

Review 8.  Intratympanic steroids as a salvage treatment for sudden sensorineural hearing loss? A meta-analysis.

Authors:  Jia Hui Ng; Roger Chun Man Ho; Crystal Shuk Jin Cheong; Adele Ng; Heng Wai Yuen; Raymond Yeow Seng Ngo
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-09-13       Impact factor: 2.503

9.  [Multicenter trial for sudden hearing loss therapy - planning and concept].

Authors:  S K Plontke; M Girndt; C Meisner; R Probst; I Oerlecke; M Richter; J Steighardt; G Dreier; A Weber; I Baumann; S Plößl; J Löhler; R Laszig; J A Werner; T Rahne
Journal:  HNO       Date:  2016-04       Impact factor: 1.284

10.  The efficacy and safety of systemic injection of Ginkgo biloba extract, EGb761, in idiopathic sudden sensorineural hearing loss: a randomized placebo-controlled clinical trial.

Authors:  Ja-Won Koo; Mun Young Chang; Sung-Cheol Yun; Tae Su Kim; Soo-Keun Kong; Jong Woo Chung; Eui-Kyung Goh
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-11-11       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.